IRVINE, Calif., Aug. 11, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis based medicines, is happy to announce their first batch order for the previously announced cannabinoid based inhalation medicine for Asthma/COPD has been placed. It is expected to be received by the company within a week and released initially in select California dispensaries and available for delivery. The CBIS MDI Rescue Inhaler dosage is targeting 100 – 200 dose MDI with cannabinoid level variations ranging from 10mg, 25mg, up to 100mg THC, CBD, and other cannabinoid variables as patient/consumer analysis moves further down the road.
Based on State-by-State laws the Company can proceed with studies in the 25+ states approved for medical marijuana, and lay the groundwork for expanding into other states across the nation as legislation changes and more states become legal. This could also be seen as a mechanism to verify the effectiveness of CBD/THC on patients that use the medication as a bronchodilator.
This MDI device offers the ingestion of the Medication in a finer Particle mist than the Nebulizer version which can be quickly absorbed by the Lungs and spread into the Blood Stream for quicker response time. Rescue Inhalers cannot replace Nebulizer Medications but the portability of these devices gives the Asthma/COPD sufferer freedom to be out enjoying life knowing their medication is at hand if needed.
The CBIS MDI Rescue Inhaler is expected to be available in all states where marijuana is legal and medical users will typically be patients with nebulizer usage experience. Studies have shown that CBD/THC can often be a more effective bronchial dilator than Albuterol or Ipratropium, some of the leading asthma products on today’s market. In many studies THC and CBD oil ingestion was found to have better response times to induced flare ups of the patients studied.
A metered dose inhaler (MDI) is a handheld device that delivers a specific amount of medication in aerosol form, rather than as a pill or capsule. The MDI consists of a pressurized canister inside a plastic case, with a mouthpiece attached. With an MDI, you press on the device while inhaling the Asthma/COPD medication directly into your lungs. Its portability makes it easy to use anywhere, anytime. MDIs use a propellant to push medication out of the inhaler.
Rescue Inhalers are designed to be used as needed for rapid, short-term relief of symptoms — used to prevent or treat an asthma/COPD attack.
“We couldn’t be more excited to expand our company’s reach to impact more patients than ever in a positive way,” said President & CEO, Co-Founder, Raymond C. Dabney. “It surprises people that cannabis can actually improve lung volume and air flow rates, but that’s exactly what studies show. We are glad to be one of the first to bring such an effective, natural treatment to market. The Cannabis Science Cannabinoid Based Inhalant will first be distributed in the State of California, but we plan to quickly roll the product out across the nation in legal States.”
These exciting new medical applications have opened doors to a huge market of medical marijuana and cannabinoid patients that were left out do to the harmful effects of smoking Marijuana to receive the benefits needed.
How Cannabinoids may help Asthma/COPD:
- Cannabinoids can relieve inflammation
- Cannabinoids can be anti-microbial
- Cannabinoids can support / modulate the immune system and its response to infection and disease
- Cannabinoids can be expectorants
- Cannabinoids are analgesic (pain relief)
- Cannabinoid medicine has little to no side effects
How THC May Help Asthma/COPD:
(1) THC seems to produce faster symptomatic relief than Proventil, and speed is important when you’re having trouble breathing.
(2) THC seems to increase lung capacity and produce deeper breathing than Proventil.
(3) THC seems to enable deeper breaths than when not under attacks. There are a number of objective tests of lung capacity that have shown this theory to be true.
(4) THC does tend to make you sleepy, which actually makes it perfect for right before you go to bed, when consistently the need to use Proventil to prevent the asthma/COPD attack that inevitably starts as soon as you lie down.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of a unique understanding of biologic processes to provide novel treatment approaches for common ailments and for those disorders where current treatments are relatively unsuccessful and understanding remain incomplete. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the increasingly complex underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3044297
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder